Axe Compute has reshaped its board following the third-quarter sale of its Helomics subsidiary, with three directors resigning and CEO Christopher Miglino taking over as board chair. The company says it is seeking new directors with experience relevant to its core business and is in advanced stages of evaluating candidates.
The changes leave the board with four members and three vacancies. The company also arranged consulting work with the departing directors to help with the transition, including on legacy life-sciences and pharmaceutical matters.
Key details
- Charles L. Nuzum, Daniel E. Handley and Gregory S. St. Clair resigned from the board and all its committees effective October 27. Nuzum had been board chair. The company said the departures were not prompted by disagreements over its operations, policies or practices.
- After the resignations, three of the four remaining directors are independent. The board reorganized its standing committees on November 2; the audit, compensation, and nominating and governance committees each continue to meet Nasdaq’s composition requirements.
- Miglino, the company’s chief executive and a director, became board chair on November 1, succeeding Nuzum. He will receive no additional compensation for the role.
- The company is evaluating candidates to fill the three board vacancies, with a focus on experience relevant to its core business after the Helomics divestiture.
- Each departing director agreed to be reasonably available to advise the board and management during the transition. For that work and a release of claims in favor of the company, Handley will receive $120,000 in cash. Nuzum and St. Clair will each receive restricted company shares valued at $150,000, which will vest in full six months after their consulting agreements take effect.
- All three departing directors will also receive the board cash retainers and committee fees they would have earned through December 31, 2026.
What changes
Miglino now holds both the chief executive and board chair roles. The board has three open seats, but its remaining members retain a majority of independent directors, and its committees continue to satisfy Nasdaq’s composition requirements. The departing directors’ consulting arrangements provide for transition support while the company pursues its board refresh.